Targeting cancer cells with nucleic acid aptamers

Trends in Biotechnology

Volumn 28, Issue 10, 2010, Pages 517-525

  Cerchia, Laura ^a   de Franciscis, Vittorio ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMERS; BIOCONJUGATES; CANCER CELLS; CELL RECOGNITION; CELL SURFACES; CLINICAL DIAGNOSIS; HIGH AFFINITY; HIGH SPECIFICITY; IN-VIVO; LOW TOXICITY; MOLECULAR IMAGING; NOVEL APPLICATIONS; NUCLEIC ACID APTAMERS; SMALL INTERFERING RNA; TARGET MOLECULE; TRANS-MEMBRANE PROTEINS;

CELL MEMBRANES; DIAGNOSIS; NUCLEIC ACIDS; RNA;

MOLECULES;

APTAMER; DOXORUBICIN; NUCLEIC ACID; PEGAPTANIB; TECHNETIUM 99M;

CANCER CELL; CANCER DIAGNOSIS; CELL SURFACE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; APTAMERS, NUCLEOTIDE; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; NEOPLASMS;

EID: 77956876990     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.07.005     Document Type: Review

References (70)

1. Famulok M., et al. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem. Rev. 2007, 107:3715-3743.
2. Eaton B.E., et al. Let's get specific: the relationship between specificity and affinity. Chem. Biol. 1995, 2:633-638.
3. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
4. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
5. Cerchia L., et al. Cell-specific aptamers for targeted therapies. Methods Mol. Biol. 2009, 535:59-78.
6. Thiel K.W., et al. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 2009, 19:209-222.
7. Ferreira C.S., et al. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006, 27:289-301.
8. Lupold S.E., et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002, 62:4029-4033.
9. Chen C.H., et al. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9226-9231.
10. Li N., et al. Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. (Camb). 2010, 46:392-394.
11. Liu Y., et al. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol. Chem. 2009, 390:137-144.
12. Cerchia L., et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 2005, 3:e123.
13. Pestourie C., et al. Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides 2006, 16:323-335.
14. Ohuchi S.P., et al. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie 2006, 88:897-904.
15. Vento M.T., et al. Distribution and bioactivity of the Ret-specific D4 aptamer in three-dimensional collagen gel cultures. Mol. Cancer Ther. 2008, 7:3381-3388.
16. Esposito C.L., et al. A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS One 2008, 3:e1643.
17. Hicke B.J., et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 2001, 276:48644-48654.
18. Morris K.N., et al. High affinity ligands from in vitro selection: complex targets. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2902-2907.
19. Shangguan D., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11838-11843.
20. Shangguan D., et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 2008, 7:2133-2139.
21. Sefah K., et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009, 23:235-244.
22. Chen H.W., et al. Molecular recognition of small-cell lung cancer cells using aptamers. Chem. Med. Chem. 2008, 3:991-1001.
23. Blank M., et al. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem. 2001, 276:16464-16468.
24. Daniels D.A., et al. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15416-15421.
25. Raddatz M.S., et al. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed. Engl. 2008, 47:5190-5193.
26. Cerchia L., et al. Differential SELEX in human glioma cell lines. PLoS One 2009, 4:e7971.
27. Mallikaratchy P., et al. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol. Cell Proteomics 2007, 6:2230-2238.
28. Golden M.C., et al. Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J. Biotechnol. 2000, 81:167-178.
29. Golden M.C., et al. Mass spectral characterization of a protein-nucleic acid photocrosslink. Protein Sci. 1999, 8:2806-2812.
30. Bates P.J., et al. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. 1999, 274:26369-26377.
31. Bates P.J., et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009, 86:151-164.
32. Mongelard F., Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 2010, 12:107-114.
33. Ng E.W.M., et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5:123-132.
34. Zhou J., Rossi J.J. Aptamer-targeted cell-specific RNA interference. Silence 2010, 1:4.
35. Farokhzad O.C., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6315-6320.
36. Bagalkot V., et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 2006, 45:8149-8152.
37. Chu T.C., et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006, 66:5989-5992.
38. Chen C.H., et al. Aptamer-based endocytosis of a lysosomal enzyme. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15908-15913.
39. Hicke B.J., et al. Tumor targeting by an aptamer. J. Nucl. Med. 2006, 47:668-678.
40. Tong G.J., et al. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc. 2009, 131:11174-11178.
41. McNamara J.O., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
42. Dassie J.P., et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 2009, 27:839-849.
43. Chu T.C., et al. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34:e73.
44. Wullner U., et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets 2008, 8:554-565.
45. Zhou J., et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37:3094-3109.
46. Guo S., et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum. Gene Ther. 2005, 16:1097-1109.
47. Pastor F., et al. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010, 465:227-231.
48. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur. J. Immunol. 2006, 36:1222-1230.
49. Bouchard P.R., et al. Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 2010, 50:237-257.
50. Shieh, F. et al. (2005) Semiconductor nanocrystal-aptamer bioconjugate probes for specific prostate carcinoma cell targeting. Nanobiophotonics and Biomedical Applications II, Cartwright A.N. and Osinski M. Edits, Proc. SPIE, 5705, 159-165.
51. Dhar S., et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17356-17361.
52. Wang A.Z., et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem. Med. Chem. 2008, 3:1311-1315.
53. Zhang L., et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2007, 2:1268-1271.
54. Huang Y.F., et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chem. Bio. Chem. 2009, 10:862-868.
55. Huang Y.F., et al. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 2008, 24:11860-11865.
56. Ko M.H., et al. In vitro derby imaging of cancer biomarkers using quantum dots. Small 2009, 5:1207-1212.
57. Cheng A.K., et al. Aptamer-based detection of epithelial tumor marker mucin 1 with quantum dot-based fluorescence readout. Anal. Chem. 2009, 81:6130-6139.
58. Ferreira C.S., et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009, 37:866-876.
59. Tavitian B., et al. In vivo imaging of oligonucleotidic aptamers. Methods Mol. Biol. 2009, 535:241-259.
60. Tavitian B., et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat. Med. 1998, 4:467-471.
61. Perkins A.C., Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q. J. Nucl. Med. Mol. Imaging 2007, 51:292-296.
62. Borbas K.E., et al. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug. Chem. 2007, 18:1205-1212.
63. Pieve C.D., et al. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl. Med. Biol. 2009, 36:703-710.
64. Hwang do W., et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med. 2010, 51:98-105.
65. Tu L.C., et al. Targeting stem cells-clinical implications for cancer therapy. Curr. Stem Cell Res. Ther. 2009, 4:147-153.
66. Guo K.T., et al. A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 2006, 24:2220-2231.
67. Hoffmann J., et al. Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J. Biomed. Mater. Res. A. 2008, 84:614-621.
68. Ashworth T.R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 1869, 14:146-149.
69. Goodale D., et al. Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry A 2009, 75:344-355.
70. Mi J., et al. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 2010, 6:22-24.